AI Article Synopsis
- The study aimed to assess the presence of CK-19 and CK-20 in bladder cancer tissues and IL-6 in the blood of Egyptian patients, while correlating these findings with clinical factors and the influence of Bilharziasis.
- Bladder cancer tissues showed expression of CK-19 and CK-20, which correlated with more advanced cancer stages and grades, while IL-6 levels in the blood were linked to malignancy and tumor type.
- The findings suggest that CK-19, CK-20, and IL-6 could serve as useful markers for evaluating bladder cancer in patients.
Article Abstract
Objectives: This study was designed to detect the expression of CK-19 and CK-20 in tissue specimens and IL-6 in the sera (as a noninvasive maneuver) of bladder cancer patients. Results were correlated with the clinico-pathologic parameters, Bilharziasis and the occurrence of relapse of the carcinoma among Egyptian bladder cancer patients.
Methods: Subjects of this study were 50 cases of bladder carcinoma (19 cases were positive for Bilharziasis) as well as 20 cystitis cases as control (7 cases were positive for Bilharziasis). Messenger ribonucleic acid extracted from fresh frozen tissue specimens with bladder tumor and the control group were collected and subjected to RT-PCR to detect expression of the amplification bands of CK-19 and CK-20 (214 and 370 base pairs). In the mean time, Interleukin-6 was quantified in the sera of the patients using ELISA kit.
Results: CK-19 and CK-20 RNAs were expressed in bladder cancer cases, but not expressed in the control group. They were significantly correlated to advanced tumor stage and grade, while CK-19 positivity, was also, correlated to tumor recurrence and tumor pathology being more in SCC than TCC. Moreover, IL-6 positivity was correlated to the occurrence of malignancy, advanced grade and pathology being more in SCC than TCC. ROC curve was utilized to choose the best cut-off for serum IL-6 (49.2 pg/mL). At the determined cut-off, the sensitivity was 66% and the specificity was 95%. Bilharziasis was found to be related to advanced stages and grades of bladder cancer.
Conclusion: CK-19, CK-20 and IL-6 were strongly associated with malignant phenotype of Egyptian bladder tissues, so they may be used as additional markers for assessment of bladder cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0009-9120(02)00382-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.
Explor Target Antitumor Ther
November 2024
Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatment of aUC has evolved and been enriched with new classes of drugs that demonstrated pivotal improvements in terms of oncological responses and, ultimately, survival.
View Article and Find Full Text PDFBeta-human chorionic gonadotropin, carbohydrate antigen 19-9, cancer antigen 125, and carcinoembryonic antigen as prognostic and predictive biological markers in bladder cancer.
Front Oncol
December 2024
Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.
Introduction: We evaluated the prognostic potential of the Beta-human chorionic gonadotropin (β-hCG), Carbohydrate Antigen 19-9 (CA19-9), Cancer Antigen 125 (CA125), and Carcinoembryonic Antigen (CEA) tumor markers for bladder cancer.
Methods: We analyzed the records of 369 patients who underwent radical cystectomy for urothelial cancer (UC) between October 2012 until December 2019. Levels of CA19-9, CA125, CEA, and β-hCG before radical cystectomy were measured in all patient samples, and serum biomarker cutoff values were used as normal and elevated values.
Perivascular Epithelioid-Cell Tumour of the Bladder: A Case Report.
Arch Esp Urol
December 2024
Department of Urology, Kocaeli University Faculty of Medicine, 41001 İzmit, Turkey.
Background: Perivascular epithelioid-cell tumour (PEComa) is a rare mesenchymal tumour with low malignant potential. PEComa can be found in many organs throughout the body. In the urinary system, it can be found in the prostate, bladder, and kidney.
View Article and Find Full Text PDF[Efficacy and Adverse Events of Low-Dose Intravesical BCG Therapy for Non-Muscle-Invasive Bladder Cancer].
Hinyokika Kiyo
December 2024
The Department of Urology, Morinomiya Hospital.
We examined the efficacy and adverse effects of low-dose intravesical Bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle-invasive bladder cancer. Patients who underwent intravesical BCG therapy (n＝176 ; 198 courses) at our hospital between April 2012 and December 2022 were enrolled. After assigning patients to either the low-dose or regular-dose (40 or 80 mg of BCG Tokyo 172 strain) groups, treatment efficacy and incidence of adverse events were compared.
View Article and Find Full Text PDFThe N-methyladenosine methyltransferase TRMT61A promotes bladder cancer progression and is targetable by small molecule compounds.
Clin Transl Med
January 2025
Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!